Findings
There are gaps in assessing aspects of physical function that matter to patients.
Existing assessment methods have limitations, including their episodic nature and burden to patients.
There are currently no approved drugs in the United States for the treatment of cancer cachexia.

Recommendations
Develop and validate digital measures of health.
Ensure digital measures are meaningful to patients.
Qualify digital measures for use in clinical development and regulatory decision-making.

Regulatory Considerations
Qualification of digital measures as drug development tools is necessary.
Digital measures are gaining traction in regulatory decision-making.
The FDA recommends qualification of digital measures in their PFDD guidelines.”